US 12,121,514 B2
Nonselective metabotropic glutamate receptor activators for treatment of attention deficit disorder and 22Q syndrome
Hakon Hakonarson, Malvern, PA (US); and Charlly Kao, Philadelphia, PA (US)
Assigned to THE CHILDREN'S HOSPITAL OF PHILADELPHIA
Filed by THE CHILDREN'S HOSPITAL OF PHILADELPHIA, Philadelphia, PA (US)
Filed on Dec. 17, 2020, as Appl. No. 17/125,164.
Application 15/850,307 is a division of application No. 15/258,828, filed on Sep. 7, 2016, granted, now 9,884,057.
Application 17/125,164 is a continuation of application No. 15/850,307, filed on Dec. 21, 2017, granted, now 10,869,861.
Claims priority of provisional application 62/215,633, filed on Sep. 8, 2015.
Claims priority of provisional application 62/215,636, filed on Sep. 8, 2015.
Claims priority of provisional application 62/215,673, filed on Sep. 8, 2015.
Claims priority of provisional application 62/215,628, filed on Sep. 8, 2015.
Prior Publication US 2021/0205288 A1, Jul. 8, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/454 (2006.01); A61K 45/06 (2006.01); C12Q 1/6883 (2018.01)
CPC A61K 31/454 (2013.01) [A61K 45/06 (2013.01); C12Q 1/6883 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01)] 18 Claims
 
1. A method of treating 22q deletion and/or duplication syndrome in a subject comprising administering an effective amount of fasoracetam to a subject with 22q deletion and/or duplication syndrome, thereby treating 22q deletion and/or duplication syndrome, wherein the subject has at least one of oppositional defiant disorder (ODD), anxiety disorder, conduct disorder, Tourette's syndrome, autism, difficulty controlling anger, disruptive behavior, a mood disorder, a phobia, obsessive compulsive disorder (OCD), dermatillomania, a developmental disorder, or a movement disorder.